Inspire Medical Stock Falls Despite Solid Preliminary Q4 Revenues

Financial Performance - Preliminary Q4 2024 revenues estimated between $239.5 million and $239.7 million, up 25% YoY, surpassing Zacks Consensus Estimate of $233 million [2] - Full-year 2024 revenues estimated between $802.6 million and $802.8 million, up 28% from 2023, exceeding Zacks Consensus Estimate of $796.1 million [5] - 2025 revenue guidance projected between $940 million and $955 million, reflecting 17-19% growth over 2024, with Zacks Consensus Estimate at $949.4 million [6] Business Expansion - Activated 72 new US medical centers in Q4 2024, bringing total to 1,435 centers implanting Inspire therapy [3] - Created 12 new US sales territories in Q4 2024, increasing total to 335 territories [3] - Implemented new organizational structure to fuel growth, including leadership team expansion [4] Product Development - Soft launched Inspire V neurostimulator in Q4 2024, with over 40 implants completed in Singapore and the US [7] - Introduced SleepSync programming system in Q3 2024, with full US availability expected in 2024 [12] Market Performance - Shares plunged 13.4% at yesterday's closing despite robust preliminary results [1] - Shares lost 11.4% between Oct 1 and Dec 31, 2024, compared to industry's 4.9% decline and S&P 500's 3.7% gain [10] Industry Comparison - Cencora (COR) gained 0.2% against industry's 12.7% decline between Oct 1 and Dec 31, 2024 [11] - Boston Scientific (BSX) rallied 6.2% against industry's 4.1% decline between Oct 1 and Dec 31, 2024 [14] - Cardinal Health (CAH) gained 7.2% compared to industry's 0.8% growth between Oct 1 and Dec 31, 2024 [16]